4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazine-1-carbaldehyde hydrochloride

Catalog No. :
ACFHVI220
CAS No. :
84050-21-5
Molecular Formula :
C15H20ClN5O3
Molecular Weight :
353.81

IUPAC Name:4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazine-1-carbaldehyde hydrochloride

4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazine-1-carbaldehyde hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazine-1-carbaldehyde hydrochloride
IUPAC Name4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazine-1-carbaldehyde hydrochloride
Molecular FormulaC15H20ClN5O3
Molecular Weight353.81
SMILESO=CN1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1.[H]Cl
InChI KeyWLBHLVFARVXOAD-UHFFFAOYSA-N
SynonymTerazosin Impurity 4(Terazosin EP Impurity D);Terazosin EP IMpurity D;Terazosin EP IMP D;1-(4-Amino-6,7-dimethoxyquinazolin-;1-(4-Amino-6,7- dimethoxyquinazolin-2-yl)-4-formylpiperazine Hydrochloride;Terazosin Impurity D;Terazosin Hydrochloride Dihydrate Impurity D as Hydrochloride;Terazosin Hydrochloride Dihydrate EP Impurity D as Hydrochloride
CAS No.84050-21-5

Synthetic Route by SureRoute

1. ACFHVI220 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRQHE063 route compound structure diagram
    ACRQHE06360548-08-5 In Stock
  2. Plus
  3. ACEDMW612 route compound structure diagram
    ACEDMW6126108-23-2 In Stock
  4. Then
  5. ACFHVI220 route product structure diagram
    ACFHVI22084050-21-5
Inquiry

2. ACFHVI220 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRQHE063 route compound structure diagram
    ACRQHE06360548-08-5 In Stock
  4. Then
  5. ACFHVI220 route product structure diagram
    ACFHVI22084050-21-5
Inquiry

Comments (0)